Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanosonics Limited ( (AU:NAN) ) has provided an update.
Nanosonics Limited reported strong financial results for the full year 2025, showcasing a 17% year-over-year increase in total revenue to $198.6 million. The company’s recurring revenue, which includes consumables and services, grew by 20% to $146.1 million, highlighting the robustness of its business model. Capital revenue also saw a 9% increase, while the gross profit margin slightly improved to 78.2%. Operating expenses rose by 10%, but the consolidated profit before tax surged by 72% to $22.3 million, indicating a solid financial performance and positive outlook for stakeholders.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited operates in the infection prevention industry, focusing on providing innovative solutions for healthcare settings. The company is known for its products and services that aim to prevent infections, with a significant emphasis on recurring revenue from consumables and services.
Average Trading Volume: 725,502
Technical Sentiment Signal: Buy
Current Market Cap: A$1.23B
See more data about NAN stock on TipRanks’ Stock Analysis page.